Knome develops systems and services for human genome interpretation, combining analytical and workflow software with grid computing. Its integrated offering includes knoSOFT (analytical and workflow software) and the knoSYS™100 grid computing platform. The company leverages bioinformatics expertise and a proprietary technology platform to support researchers, drug developers, and clinicians in determining the genetic basis of disease and drug response. Knome is developing its technology into products that support clinical laboratory operations. The company intends to use the financing to expand its genomic services and software systems businesses. Knome is led by CEO Wolfgang Daum. Knome is a Cambridge, MA–based life science company specializing in the interpretation and comparison of human genomes. The company provides human whole-genome analysis services and was the first organization to offer commercial whole-genome analysis shortly after Watson and Venter were sequenced. Knome was founded in 2007 by a team who believed human genomics could transform health and medicine and is led by George Church, Professor of Genetics at Harvard Medical School. Its core product is whole-genome interpretation and comparative analysis for human genomes. The article does not disclose customers, revenue, or user metrics. Knome has raised $5 million in venture capital, according to an SEC filing.

Total raised

$18M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2014